Physician profile
Michael T Vu
NPI 1548201122
$1,840.41
in general payments reported to CMS, 2019-2025
12 companies · $665 in 2025
The $665 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $162 · 2021: $130 · 2022: $109 · 2023: $163 · 2024: $183 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $993 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $993.39 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $384.07 | 2019-2025 | Rocklatan, Tryptyr |
| Bausch & Lomb Americas INC. | $340.71 | 2023-2025 | Envista Envy Iol, Miebo, Vyzulta |
| Amgen INC. | $280.52 | 2020-2025 | Tepezza |
| Abbott Laboratories | $222.20 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit, Xact |
| Johnson & Johnson Surgical Vision, INC. | $148.88 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $122.54 | 2019-2021 | |
| Lilly USA, LLC | $120.30 | 2023 | Mounjaro |
| Carl Zeiss Meditec, INC. | $95.00 | 2019 | |
| Rayner Intraocular Lenses Limited | $67.34 | 2025 | Omidria |
| Horizon Therapeutics Plc | $24.88 | 2023 | Tepezza |
| Oyster Point Pharma, INC. | $19.53 | 2024 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $14.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.